20 Posts Not To Miss From ESGO 2025

The 26th European Congress on Gynaecological Oncology (ESGO 2025) took place in Rome, Italy, from February 20-23.

Organized by the European Society of Gynaecological Oncology (ESGO), this congress is Europe’s largest gathering dedicated to gynecological cancers, featuring cutting-edge research, clinical advancements, and innovative treatment approaches.

With 50+ scientific sessions, state-of-the-art lectures, interactive discussions, surgical video presentations, and tumor board sessions, ESGO 2025 provided a comprehensive platform to exchange knowledge, enhance skills, and advance the field. Throughout the event, social media was buzzing with key takeaways, expert insights, and memorable moments.

Our team at OncoDaily has selected a few highlights from ESGO 2025 that you should not miss.

Sergi Fernandez:

“A truly inspiring ESGO2025 with:

• Patient testimonials on hereditary gynecologic cancer risk,
• Live surgeries,
• Honorary recognition of Denis Querleu,
• Nearly 4000 participants!

Congratulations! We keep growing!”

Imen Sassi:

“Great insights from Dr. Jaidane from Institut Salah Azaiez, sharing the Tunisian experience in the Tumor Board Addressing Resource Challenges session, moderated by Dr. Basel Refky.

A valuable discussion on optimizing cancer care with limited resources!”

ESGO:

“We caught up with ESGO President Anna Fagotti after last night’s closing ceremony at the ESGO2025 Congress in Rome!

In addition to being grateful for the wonderful networking experiences, she extends a huge thank you to Isabelle Ray-Coquard and the Programme Committee for making this an exciting, high-quality scientific event.

Today the 2025 Congress fully wraps up with some post-Congress workshops and meetings.”

Proceed to the video attached to the post.

Enrique Chacón:

“Just published the results of the SUROVA Study in ESGO 2025!

We are very grateful to all our collaborators because without them it would not have been possible!”

Esra Bilir:

Women Empowerment!

This photo is just the tip of the iceberg, a glimpse of the incredible women Sara Nasser, Aleksandra Strojna, and Joanna Kacperczyk-Bartnik in my life. These are the people who walk beside me, have my back, and lead the way ahead. Not all of them are in this picture, but each one plays a vital role in shaping the person and physician I am today.

We all have our strengths, weaknesses, similarities, and differences, but the beauty lies in the way we truly know, accept, and celebrate each other. I feel incredibly lucky to be surrounded by such powerful women who are my mentors, my friends, my colleagues, also mothers, leaders, top surgeons, and so much more…

If you ever need someone to listen to you, support you, or just walk beside you, I’m here for you. That’s the lesson I’ve learned from my mentors, the pioneers in gynecologic oncology. Even just knowing their names helped me get into medical school (Prof. Christina Fotopoulou and Prof. Anna Fagotti (secret revealed)).

Over the years, I’ve had the privilege of connecting with them personally through the European Society of Gynaecological Oncology, ENYGO, and PARSGO – The Pan-Arabian Research Society of Gynecological Oncology communities.

Life is short, and what matters most is the love we leave behind.

WE DO OUR BEST for THE WOMEN.

Taro Yamanaka:

“The results of the phase Ⅲ ENGOT-OV43/GOG3036/KEYLYNK-001 trial were presented for the first time, demonstrating a statistically significant improvement in the primary endpoint of PFS.

However, the additional benefit of ICI in combination with PARPi remains unclear.”

Eshwarya Kaur:

A fantastic end to three incredible days at ESGO2025!

The highlight was of course hearing the legendary Prof. Vergote speak at the Late Breaking Abstracts session – truly exceptional!

Basel Refky:

The end of the unforgettable European Society of Gynaecological Oncology 2025 meeting, with the largest gathering of 4000 attendees in Rome from all world corners, outstanding program, and discussions, started with the very sad news of the loss of Great Prof. Scambia in the first day and ended by thanking him and singing for Rome.

I had the privilege of chairing and speaking in two sessions about endometrial cancer and resource-stratified cervical cancer ESGO guidelines launching and meeting plenty of friends.

Flying back to Cairo with great memories.

Ilaria Colombo:

“Honored to have participated in ESGO 2025 and meet with colleagues and friends representing IOSI Oncology Institute of Southern Switzerland – EOC Ente Ospedaliero Cantonale (EOC).

This year’s event was particularly heartbreaking as we collectively reflected on the profound loss within our scientific community. It was a moment that reminded us of the fragility of life and the importance of our work.

Let us continue to honor those we’ve lost by striving for excellence and pushing the boundaries of our research.”

Victor Heurtier:

“A huge thank you to AERIO and France National Institute of Cancer for supporting oncology residents in France with travel grants for conference attendance.

A great opportunity for me to reach Roma for the European Society of Gynaecological Oncology 2025 conference.

Looking forward to presenting my poster tomorrow.

Join me at poster S086 to discuss the gynecological carcinosarcoma and molecular oncology.”

Kristina Lindemann:

“Stand-up poster discussion of some of the Norwegian contributions to the ESGO meeting in Rome.

Great to see data emerging on:

• Use of aspirin and NA-NSAIDS and risk of endometrial cancer presented by my PhD student Ala Jabri Haug,
• Real-world data on the efficacy and safety of immune checkpoint inhibitors from our NEON cohort of patients with cervical cancer,
• Trends in lymph node staging in endometrial cancer and other results from the Sensor study,
•  Long-term follow-up of patients treated with granulosa cell tumors,

and many more.

Gratulation to all presenters.”

Maciej Stukan:

“At Szpitale Pomorskie we treat patients with advanced ovarian cancer. It is the work of a whole team of people, in a well-organized infrastructure of the Hospital.

We take part in international research to answer our questions and to treat in accordance with the best standards, safely and effectively.

The study, the results of which have just been presented at the ESGO 2025, shows that patients with advanced ovarian cancer, in whom it is possible to remove all foci of the disease during the so-called primary cytoreductive surgery (which is the beginning of treatment) (even at the expense of large complex surgery) and do not develop complications, have the best oncological results.

Therefore, two elements are crucial:

• A specific assessment of the risk of complications, active preparation of the patient for this major surgery, and carrying out this treatment using all possible measures and multidisciplinary cooperation to minimize the risk of complications,
• The ability to excise all lesions and skills to carry out such a comprehensive treatment.

Then, of course, there must be a smooth transition to systemic treatment, which is also carried out in Poland according to the best standards, with access to drug programs and clinical trials.”

Caterina Gianni:

“Excited to present our work at my first ESGO 2025 conference in Rome!

We shared real-world data on the correlation between hormonal therapy prescribed for endometriosis and the risk of developing breast cancer, ovarian cancer, and endometrial cancer.

Grateful for the ongoing collaboration with TriNetX —looking forward to more insights ahead!”

Fatih Gücer:

The new ESGO 2025 guideline, as presented at the congress, marks a significant shift in the approach to the surgical management of endometrial carcinoma confined to the uterus.

According to the update, the requirement for systematic lymphadenectomy is no longer emphasized. Instead, the focus is on sentinel lymph node dissection, regardless of the histological type of cancer.

Victor Heurtier:

“Honored to have my poster at the ESGO 2025 conference selected for the ‘Commented Posters Session’, alongside 3 colleagues, from over a hundred posters presented yesterday.

Thanks to everyone who attended the discussion session and stopped by the poster throughout the day to discuss our results.

Many thanks to everyone involved in the ROCSAN trial, which I had the privilege of analyzing some of the molecular data from.”

Christos Iavazzo:

Live surgery ESGO2025!

Congratulations to Henrik Falconer for presenting to us the pathways toward the sentinel lymph nodes based on the RACC trial protocol.

Hans Wenzel:

Proud to be able to show our research on chemotherapy in patients with advanced ovarian cancer on day 2 of ESGO 2025. Of the 3,678 women in our national study, more than half (!) underwent chemotherapy adjustment, with dose reductions being the most common (38%). Remarkably, we did not find that dose reductions are associated with lower survival!

Although retrospective research does not show causal relationships, these results indicate that future prospective studies should further investigate the impact of lower chemotherapy doses. Let’s work together on better treatment outcomes for women with ovarian cancer!

Thanks to first author Sherin Said and co-authors Anne van Altena, Janneke Walraven, Joanna in ‘t Hout, Joanne de Hullu, and Maaike Welpelo-van der Aa, for this beautiful collaboration between Radboudumc and IKNL (Integraal Kankercentrum Nederland).

Interested in the details? Please send us a message! We expect to publish the full study next spring.

The summary can be found here.

Virginia Lazar:

“During his life, Carl Gustav Jung said: ‘We never heal anything, we just give up!’

If he would live today, he would be impressed. Genomic research and targeted cancer therapies are changing the world: less invasive surgery, 85% 5 years survival in Western countries.

Women diagnosed with cancer are able to become healthy mothers of healthy babies.

The message I want to leave you with this evening is what I saw on a presentation held by a pioneer in cancer and pregnancy research: ‘Cancer in pregnancy is not an emergency, there is time for deliberation and second opinion’.”

Pierre Descargues:

“Nice oral communication from Pierre-Adrien Bolze, MD, PhD at the European Society of Gynaecological Oncology Congress 2025 in Roma about the TROPHAMET trial METHOTREXATE + AVELUMAB for low-risk GTN – updated analysis.

Two key messages to keep in mind:

• Very high cure rate (>96%) with the possibility to eradicate low-risk GTN
• Safety data about fertility after ICI (86% of patients get pregnant among those who attempted to).

Congratulations to all Reference Center for Trophoblastic Diseases (CRMT) team who participate daily to improve patient care in this field.”

Robert Coleman:

“Great session on PARPi in the current clinical climate. Patient-level decision algorithms will become more complicated and nuanced as Keylynk and FIRST report adding to data from DUO-O. Exciting options for patients ”